<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455868</url>
  </required_header>
  <id_info>
    <org_study_id>MP-10-2018-2957</org_study_id>
    <nct_id>NCT03455868</nct_id>
  </id_info>
  <brief_title>Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes</brief_title>
  <acronym>BODI</acronym>
  <official_title>Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Bone fragility is a complication of type 2 diabetes. Diabetes treatments may
      ameliorate or deteriorate bone fragility in this population. Bariatric surgery is gaining in
      popularity in people with type 2 diabetes and may impact bone health. Objectives: To evaluate
      the impact of the 2 most popular bariatric procedures worldwide (SG, RYGB) on vBMD by QCT in
      patients with type 2 diabetes; Secondary aims: (1) to identify the determinants of vBMD after
      bariatric surgery in patients with type 2; (2) to compare vBMD and its potential determinants
      after bariatric surgery with controls with a normal BMI and normoglycemia ; (3) to compare
      changes in vBMD and its potential determinants after SG (the most popular bariatric
      procedure) with obese controls without diabetes.

      Exploratory aims: (1) to evaluate the prevalence and incidence at one year of falls as well
      as vertebral and non-vertebral fractures after SG and RYGB; (2) to evaluate bone
      microarchitecture and metabolism by iliac crest bone biopsy in patients with obesity, with or
      without type 2 diabetes, before SG.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in volumetric bone mineral density (vBMD) at lumbar spine, hip, radius, tibia</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>assessed by quantitative computed tomography (QCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in N-terminal propeptide of type 1 procollagen (P1NP)</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>serum bone formation marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in osteocalcin (total and under-carboxylated)</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>serum bone formation marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone alkaline phosphatase</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>serum bone formation marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-telopeptide</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>serum bone resorption marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>diabetes control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>diabetes control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting insulin</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>hormones involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum 25-hydroxyvitamin D</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>hormones involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in parathormone (PTH)</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>hormones involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estradiol and estrange</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>hormones involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin like growth factor (IGF)-1</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>hormones involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sclerostin</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>hormones involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in adiponectin</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>hormones involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leptin</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>hormones involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peptide YY (PYY)</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>hormones involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ghrelin</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>hormones involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fat and lean mass by dual-energy X-ray absorptiometry (DXA)</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>body composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral and subcutaneous adipose tissue by quantitative computed tomography (QCT)</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>body composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle fat content by quantitative computed tomography (QCT)</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>body composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone marrow adiposity by dual-energy quantitative computed tomography (QCT)</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>body composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in upper extremity muscle strength</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>by hand grip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lower extremity muscle strength</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>knee extensor strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle mass (muscle cross-sectional area) and function</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>by timed up and go test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle mass (muscle cross-sectional area) and function</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>by 6-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle function</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>by Fullerton Advanced Balance (FAB) Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sociodemographic factors</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in nutrition</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>3 web-based 24-h recalls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in reported physical activity</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>by questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in measured physical activity</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>by accelerometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiota</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>stool sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in menopausal status (Follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol)</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cutaneous Advanced glycation end products (AGEs)</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>skin autofluorescence</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bone microarchitecture and metabolism</measure>
    <time_frame>before surgery</time_frame>
    <description>by iliac crest bone biopsy after tetracycline labelling using standard histomorphometry, only for the SG groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Prevalence and incidence of vertebral fractures (by a CT scout of T4-L5)</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>Using the algorithm-based qualitative method (ABQ) and the Genant method and non-vertebral fractures (self-reported)</description>
  </other_outcome>
  <other_outcome>
    <measure>Prevalence and incidence of falls</measure>
    <time_frame>before and 1 year after bariatric surgery</time_frame>
    <description>by questionnaire</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Bariatric Surgery</condition>
  <condition>Bone Health</condition>
  <condition>Obesity, Morbid</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Sleeve gastrectomy diabetes</arm_group_label>
    <description>35 Men and women with type 2 diabetes and obesity undergoing bariatric surgery : Sleeve gastrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roux-in-Y gastric bypass diabetes</arm_group_label>
    <description>35 Men and women with type 2 diabetes and obesity undergoing bariatric surgery : Roux-in-Y gastric bypass</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleeve gastrectomy no diabetes</arm_group_label>
    <description>35 Men and women without type 2 diabetes and with obesity undergoing bariatric surgery : Sleeve gastrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>30 Men and women with a normal BMI and normoglycemia matched for age and sex with bariatric groups</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric surgery</intervention_name>
    <description>Sleeve gastrectomy or Roux-in-Y gastric bypass</description>
    <arm_group_label>Roux-in-Y gastric bypass diabetes</arm_group_label>
    <arm_group_label>Sleeve gastrectomy diabetes</arm_group_label>
    <arm_group_label>Sleeve gastrectomy no diabetes</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (serum and plasma)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a multi-centre, prospective and observational study comprising 2 bariatric groups
        with diabetes undergoing SG or RYGB (n=70), one bariatric group without diabetes undergoing
        SG (n=35) and one control group (n=30). Bariatric groups will include adult men and women
        with or without type 2 diabetes and obesity undergoing bariatric surgery and followed at 0,
        4 months, 8 months and 1 year after surgery, and the control group will consist of 30
        individuals with a normal BMI and normoglycemia matched for age, menopausal status and sex
        and assessed at a single visit.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  bariatric groups: men and women; 18 to 60 years old; with a BMI &gt;=35 kg/m2; with type
             2 diabetes: use of oral hypoglycemic agents or insulin OR 2 of the following tests
             confirming type 2 diabetes: HbA1c &gt;=6.5%; fasting glucose &gt;=7.0 mM; 2-h glucose post
             75g oral glucose tolerance test (OGTT) &gt;=11.1 mM) (guidelines.diabetes.ca);) or
             without diabetes: HbA1c &lt;6.5% AND fasting glucose &lt;7.0 mM; who are awaiting bariatric
             surgery. Control group: BMI 18.5 to 24.9 kg/m2; with normoglycemia: HbA1c &lt;6.0%,
             fasting glucose &lt;6.0 mM and 2-h glucose post 75g OGTT &lt;7.8 mM.

        Exclusion Criteria:

          -  type 1 diabetes; disease (e.g. uncontrolled thyroid disease, malabsorptive or overt
             inflammatory disorder, metabolic bone disease, creatinine clearance &lt;60 ml/min) or
             medication (e.g. glucocorticoids, anti-epileptic drugs, osteoporosis therapy and
             thiazolidinediones) affecting bone metabolism; BMI&gt;60 kg/m2; CT scan impossible to
             perform (e.g. patient too large for the gantry aperture); pregnant women or women who
             plan to become pregnant during the study or women of childbearing age who do not agree
             to take an appropriate contraceptive method during the study; history of oesophageal,
             gastric or digestive surgery; history of bariatric surgery; cancer at risk of
             recurrence during the study; Prosthesis that could interfere with interpretation of
             imaging data; Chronic severe condition or illness precluding from participation in the
             project.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Gagnon, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec - Université Laval</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Chouinard-Castonguay</last_name>
    <phone>4185254444</phone>
    <phone_ext>48729</phone_ext>
    <email>Sarah.Chouinard-Castonguay@crchudequebec.ulaval.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Research Institute of the McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3H 2R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Tardio, Dr</last_name>
      <email>vanessa.tardio@mail.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Vanessa Tardio, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de recherche du CHU de Québec - Université Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de recherche de l'IUCPQ</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Chouinard-Castonguay</last_name>
      <phone>4185254444</phone>
      <phone_ext>48729</phone_ext>
      <email>Sarah.Chouinard-Castonguay@crchudequebec.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Gagnon Claudia, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHU de Quebec-Universite Laval</investigator_affiliation>
    <investigator_full_name>Claudia Gagnon</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

